CJC-1295 research guide for Tseminyu. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Research-Grade CJC-1295 for Tseminyu Investigators
For anyone in Tseminyu trying to locate CJC-1295, the foundational reality is that this compound is available only through an online research supply market. What this means for Tseminyu researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those evaluation tools are within reach of all serious researchers. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide gives Tseminyu researchers the practical tools to verify sourcing options methodically and source research-grade CJC-1295 with confidence.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Tseminyu comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
The most reliable path to quality CJC-1295 is starting with community forums — peptide forums aggregate real purchasing experience that are more accurate than commercial vendor claims. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Keep lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Tseminyu
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.